Roberto Goméni

Endometriosis — United Kingdom

Mathematics · Physical Sciences

36h-index4.1kcitations228works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Statistical Methods in Clinical Trials(53), Treatment of Major Depression(29), Mental Health Research Topics(20), Attention Deficit Hyperactivity Disorder(19), Receptor Mechanisms and Signaling(19)

Publications228 total

<scp>AI</scp> ‐ <scp>NLME</scp> : A New Artificial Intelligence‐Driven Nonlinear Mixed Effect Modeling Approach for Analyzing Longitudinal Data in Randomized Placebo‐Controlled Clinical Trials
Clinical and Translational Science·2025· 1 citedOpen Access
A novel artificial intelligence-based methodology to predict non-specific response to treatment
Psychiatry Research·2025· 2 cited
Pharmacokinetic-Pharmacodynamic Modeling of Amantadine Extended-Release Capsule Effects on Dyskinesia in Parkinson Disease
Parkinsonism & Related Disorders·2025
Pharmacokinetic-pharmacodynamic Modeling of Amantadine Extended-release Capsule Effects on Dyskinesia in Parkinson Disease (P7-5.028)
Neurology·2025
Comparison of Different Machine Learning Methodologies for Predicting the Non‐Specific Treatment Response in Placebo Controlled Major Depressive Disorder Clinical Trials
Clinical and Translational Science·2025· 5 citedOpen Access
Model-informed approach to estimate treatment effect in placebo-controlled clinical trials using an artificial intelligence-based propensity weighting methodology to account for non-specific responses to treatment
Journal of Pharmacokinetics and Pharmacodynamics·2024· 1 citedOpen Access
Model informed approach to estimate treatment effect in placebo- controlled clinical trials using an artificial intelligence based propensity weighting methodology to account for non-specific responses to treatment
2024Open Access
Correction: Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson’s disease
Journal of Pharmacokinetics and Pharmacodynamics·2024Open Access
Comparison of Three Oral Amantadine Formulations: A Population Pharmacokinetic Study (P4-3.013)
Neurology·2024
Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson’s disease
Journal of Pharmacokinetics and Pharmacodynamics·2024· 1 citedOpen Access
Advanced Model-based Approach to Evaluate Human Plasma, Cerebrospinal Fluid, and Neuronal mTORC1 Activation Biomarkers After NV-5138 Administration in Healthy Volunteers
Clinical Therapeutics·2024· 1 citedOpen Access
Population pharmacokinetic model- and simulation-based dose selection for a phase 3 trial of subcutaneous long-acting olanzapine in adults with schizophrenia
Neuroscience Applied·2024· 1 citedOpen Access
Interpreting clinical trial outcomes complicated by placebo response with an assessment of false-negative and true-negative clinical trials in depression using propensity-weighting
Translational Psychiatry·2023· 10 citedOpen Access
A convolution‐based in <scp>vitro‐in</scp> vivo correlation model for methylphenidate hydrochloride delayed‐release and extended‐release capsule
CPT Pharmacometrics & Systems Pharmacology·2023· 2 citedOpen Access
Interpreting clinical trial outcomes marred by placebo response with an assessment of false-negative and true-negative clinical trials in depression using propensity-weighting
Research Square (Research Square)·2023Open Access
A new method for analyzing clinical trials in depression based on individual propensity to respond to placebo estimated using artificial intelligence
Psychiatry Research·2023· 7 citedOpen Access
Artificial intelligence approach for the analysis of placebo-controlled clinical trials in major depressive disorders accounting for individual propensity to respond to placebo
Translational Psychiatry·2023· 10 citedOpen Access
Evaluating the Impact of Caffeine on the Incidence of Adverse Events During Treatment with Viloxazine Extended-Release (Qelbree®) in Adults with ADHD
CNS Spectrums·2023· 2 citedOpen Access
Response of peer relations and social activities to treatment with viloxazine extended‐release capsules (Qelbree <sup>®</sup> ): A post hoc analysis of four randomized clinical trials of children and adolescents with attention‐deficit/hyperactivity disorder
Brain and Behavior·2023· 7 citedOpen Access
Artificial intelligence approach for the analysis of placebo-controlled clinical trials in major depressive disorders accounting for individual propensity to respond to placebo
Research Square (Research Square)·2023Open Access
page 1 of 12Next →

Frequent Co-authors

Françoise Bressolle(6), Icilio Cavero(6), Azmi Nasser(5), G. Bianchetti(4), Stefano Zamuner(4), Emilio Merlo‐Pich(4), Christian Heidbreder(4), F Lefèvre-Borg(4), C. Gomeni(3), Robert Alexander(3), Maurizio Fava(3), Gianluca Nucci(3), P.L. Morselli(3), Alan G. Roach(3), Paul J. Fudala(3), Roberto Sega(2), P. L. Morselli(2), P. Duvaldestin(2), France Mentré(2), M. Mitchard(2)